PCNA, Ki‐67, p53, bcl‐2 and Prognosis in Intraoral Squamous Cell Carcinoma of the Head and Neck | Zendy

Karin Nylander | Zendy; ElsyBritt Schildt | Zendy; Mikael Eriksson | Zendy; Göran Roos | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

PCNA, Ki‐67, p53, bcl‐2 and Prognosis in Intraoral Squamous Cell Carcinoma of the Head and Neck

Author(s) -

Karin Nylander,

ElsyBritt Schildt,

Mikael Eriksson,

Göran Roos

Publication year - 1997

Publication title -

analytical cellular pathology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.576

H-Index - 24

eISSN - 2210-7185

pISSN - 2210-7177

DOI - 10.1155/1997/591251

Subject(s) - proliferating cell nuclear antigen , immunohistochemistry , p53 expression , head and neck , p53 protein , basal cell , head and neck squamous cell carcinoma , pathology , head and neck cancer , epidermoid carcinoma , gene mutation , gene , cancer research , tumor suppressor gene , medicine , carcinoma , mutation , biology , cancer , carcinogenesis , genetics , surgery

Eighty patients with primary intraoral squamous cell carcinomas of the head and neck, with a follow-up of 4-14 years were analysed for clinical outcome in relation to immunohistochemical expression of PCNA, Ki-67, p53, bcl-2 and presence of mutations in the p53 gene. The tumor site was not associated with the different parameters calculated. PCNA and Ki-67 labelling showed median values of 56% and 32%, respectively, and neither antigen was of predictive value. Fifty-five percent of the tumours expressed p53, and 38 (48%) had mutations in the p53 gene. No association between the presence of p53 protein or mutations in the p53 gene and clinical outcome was found. Bcl-2 positivity was detected in a minor fraction (10%) of the tumours.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research